BMY stock flat TPTX stock surges on $4B acquisition deal (NYSE:BMY)
seekingalpha.com
news
2022-06-03 11:11:50

Maks_Lab/iStock via Getty Images Bristol Myers Squibb (NYSE:BMY) has entered into an agreement to acquire the clinical-stage precision oncology company Turning Point Therapeutics (TPTX) at a price of $76.00 per share in cash for a total consideration of $4.1B, the companies announced Friday. Turning Point (TPTX) shares have added ~116% in reaction while Bristol Myers (BMY) is trading flat in the morning hours. The acquisition is expected to be accretive to Bristol Myers' (BMY) non-GAAP earnings per share (EPS) from 2025 and up to $0.
